Monocyclic agonist of the interferon gene stimulator STING
By developing a non-nucleotide small molecule STING agonist to activate the STING pathway, the problem of insufficient activation of the STING pathway in the tumor microenvironment in existing technologies has been solved, resulting in a stronger immune response and tumor regression effect.
Patent Information
- Application Number
- CN202080071490.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2019-08-21
- Filing Date
- 2020-08-21
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2040-08-21
AI Technical Summary
Existing technologies are insufficient to effectively activate the STING pathway to trigger a systemic anti-tumor immune response in the tumor microenvironment, resulting in poor immunotherapy efficacy.
Develop non-nucleotide small molecule STING agonists to directly activate the STING signaling pathway, induce the production of type I interferon and pro-inflammatory cytokines, and enhance the anti-tumor response of immune cells.
It significantly enhanced the immune response in the tumor microenvironment, promoted T cell activation and tumor regression, and improved the efficacy of immunotherapy.
Smart Images

Figure CN114981256B_ABST
Abstract
Description
[0001] This application claims the benefit of priority to U.S. Patent Application No. 62 / 889,669, filed on August 21, 2019. Background Art
[0002] The cGAS-STING signaling pathway plays a key role in the innate immune response launched by mammalian host cells to eliminate a variety of DNA and RNA viruses. STING (Stimulator of Interferon Gene) is an endoplasmic reticulum (ER) resident signaling protein, partially localized to mitochondrial-associated membranes, which is widely expressed in both immune and non-immune cell types. In response to cyclic dinucleotides (CDNs) (including 2'-3' cGAMP produced by cyclic GMP-AMP synthase (cGAS) in response to cytoplasmic DNA), STING translocates to the perinuclear region, where it rapidly induces the production of type I interferons (IFNs) and proinflammatory cytokines in a TBK1 / IRF3-dependent manner. STING has also been found to bind directly to cytoplasmic DNA, although the physiological relevance of direct DNA sensing activity remains to be fully characterized.
[0003] Recent work suggests that STING plays an essential role in the immune response against tumor cells. Efficient tumor-induced T cell priming in the tumor microenvironment requires the production of interferon-β (IFN-b) by resident dendritic cells, and the expression of IFN-b has been shown to be dependent on the activation of the STING pathway (1). In fact, intratumoral delivery of nucleotide-based STING agonists has been shown to induce dramatic regression of established tumors in syngeneic mouse models (1). In addition, it has been shown that activation of the STING pathway contributes significantly to the anti-tumor effects of radiation through IFN-b-mediated immune responses in irradiated tumor microenvironments. SUMMARY OF THE INVENTION
[0005] In various embodiments, the present disclosure provides agonists of stimulator of interferon genes (STING), which can be used to treat tumors.
[0006] The present disclosure provides, in various embodiments, a compound of formula (IA) or a compound of formula (II), or a pharmaceutically acceptable salt thereof,
[0007]
[0008] Where X=S, -N=C(R 1 )-, or-C(R1 )=C(R 1 ).
[0009] R 1 Each is independently H, F, Cl, C1-C6-alkyl, vinyl or ethynyl (both of which may be substituted), cyano, alkoxy or haloalkyl.
[0010] R 2 Selected from: -C(O)OR, -C(O)NH(C1-C6-alkyl) (wherein the alkyl is optionally substituted), optionally substituted C3-C6-cycloalkenyl, and 3- to 10-membered heterocyclyl.
[0011] R is selected from: H, alkyl optionally substituted by -((C1-C6-alkyl)OC(O)OC1-C6-alkyl) or a 3- to 10-membered heterocyclyl, and benzyl, wherein the benzyl may be unsubstituted or substituted by methoxy or by an acid or ester isostere.
[0012] Ring A is a 5-membered or 6-membered heteroaryl group containing 1, 2 or 3 N atoms, unsubstituted or substituted with 1, 2 or 3 groups independently selected from the group consisting of: NH2, NH-benzyl (unsubstituted or substituted with methoxy, cyano, alkylnitrile, haloalkyl, hydroxymethyl, aminomethyl, aminopropyl, formamido, alkoxy),
[0013]
[0014]
[0015] The wavy lines indicate bonding locations.
[0016] In various embodiments, the compound of formula (IA) has formula (I):
[0017]
[0018] Where X is S, -N=C(R 1 )-, or-C(R 1 )=C(R 1 )-;R 1 R is H, alkyl or benzyl, wherein the benzyl group may be unsubstituted or substituted with a methoxy group or with an acid or ester isostere, such as 1,2,3,4 triazole.
[0019] In some embodiments, optionally in combination with any other embodiments described herein, Ring A comprises any of pyridazinyl, triazolyl, pyrimidinyl, or pyridinyl, any of which can be unsubstituted or substituted.
[0020] More specifically, according to illustrative embodiments, compounds of the present disclosure include any of the specific compounds shown in Table 1 below.
[0021] In addition, according to one embodiment, the present disclosure provides a method of stimulating the expression of interferon genes, comprising administering to a patient an effective dose of an agonist of stimulator of interferon genes (STING), wherein the agonist comprises a compound described herein; and a method of treating a tumor in a patient, comprising administering to a patient an effective dose of an agonist of stimulator of interferon genes (STING), wherein the agonist comprises a compound described herein.
[0022] Additionally, the methods of the present disclosure can be performed using an effective dose of any one of the specific compounds disclosed herein; see, for example, Table 1.
[0023] In various embodiments, the method of treating a tumor may further comprise administering an effective dose of a compound as disclosed herein by oral administration or intratumoral administration, or both.
[0024] In various embodiments, the method of treating a tumor may further comprise administering an effective dose of a compound as disclosed herein, wherein the administration comprises administering the compound to the patient as an antibody-drug conjugate or in a liposomal formulation.
[0025] In various embodiments, the method for treating a tumor may further include administering an effective dose of a compound as disclosed herein, and further including administering an effective dose of an immune checkpoint targeting drug. For example, the immune checkpoint targeting drug may be an anti-PD-L1 antibody, an anti-PD-1 antibody, an anti-CTLA-4 antibody, or an anti-4-1BB antibody.
[0026] In various embodiments, the method of treating a tumor may further comprise administering an effective dose of a compound as disclosed herein, and further comprising administering ionizing radiation or an anticancer drug. DETAILED DESCRIPTION OF THE INVENTION
[0028] There is great interest in developing STING pathway agonists for a variety of immuno-oncology applications. Most notably, STING pathway agonists have important potential applications as part of combination therapies involving immune checkpoint-targeted drugs in patients who have failed to respond to checkpoint blockade alone.
[0029] A robust platform was established for identifying non-nucleotide small molecule STING agonists. This was established using a preliminary assay involving a human THP-1 cell line carrying an IRF-inducible reporter with 5 copies of an IFN signaling response element. Counter screening was used to eliminate luciferase artifacts and ensure cross-species reactivity and pathway selectivity of human-rodents, involving alternative reporter constructs, rodent cell-based assays, and cGAS and STING knockout cell lines. Biochemical assays were used to identify specific targets of the identified hits, which involved cGAS enzymatic activity and STING protein binding assays.
[0030] "Treatment" within the meaning herein refers to relieving the symptoms associated with a disorder or disease, or inhibiting the further progression or deterioration of these symptoms, or preventing or preventing a disease or disorder, or curing a disease or disorder. Similarly, as used herein, an "effective amount" or "therapeutically effective amount" of a compound of the disclosure refers to such an amount of a compound: completely or partially relieving the symptoms associated with an obstacle or disorder, or stopping or slowing the further progression or deterioration of these symptoms, or preventing an obstacle or disorder or providing prevention of an obstacle or disorder. In particular, a "therapeutically effective amount" refers to an amount effective to achieve a desired therapeutic outcome at the necessary dosage and within the necessary time period. A therapeutically effective amount is also an amount in which the therapeutically beneficial effects of a compound of the disclosure exceed any toxic or deleterious effects.
[0031] When used to describe treatment of an individual suffering from a disorder, the expression "effective amount" refers to an amount or concentration of a Compound of the Disclosure that effectively inhibits or otherwise acts on STING in a tissue of the individual where STING is involved in the disorder, wherein such inhibition or other effect occurs to an extent sufficient to produce a beneficial therapeutic effect.
[0032] Generally speaking, the initial therapeutically effective amount of the compound described herein or its pharmaceutically acceptable salt administered is in the range of about 0.01 to about 200 mg / kg of patient body weight or about 0.1 to about 20 mg / kg of patient body weight per day, and the typical initial range is about 0.3 to about 15 mg / kg / day. Oral unit dosage forms (e.g., tablets and capsules) may contain about 0.1 mg to about 1000 mg of the compound or its pharmaceutically acceptable salt. In another embodiment, such a dosage form contains about 50 mg to about 500 mg of the compound or its pharmaceutically acceptable salt. In another embodiment, such a dosage form contains about 25 mg to about 200 mg of the compound or its pharmaceutically acceptable salt. In another embodiment, such a dosage form contains about 10 mg to about 100 mg of the compound or its pharmaceutically acceptable salt. In another embodiment, such a dosage form contains about 5 mg to about 50 mg of the compound or its pharmaceutically acceptable salt. In any of the above embodiments, the dosage form can be administered once a day or twice a day.
[0033] The term "pharmaceutically acceptable salt" refers to non-toxic inorganic or organic acid and / or base addition salts, see, for example, Lit, et al., Salt Selection for Basic Drugs (1986), Int J. Pharm., 33, 201-217, which is incorporated herein by reference. Representative pharmaceutically acceptable salts include, for example, alkali metal salts, alkaline earth metal salts, ammonium salts, water-soluble and water-insoluble salts, such as acetate, amsonate (4,4-diaminostilbene-2,2-disulfonate), benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, butyrate, calcium, calcium edetate, camphorsulfonate, carbonate, chloride, citrate, clavulariate, dihydrochloride, edetate, edisylate, estolate, esylate, fumarate, glucoheptonate, gluconate, glutamate, glycollylarsanilate, hexafluorophosphate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydroxynaphthoate Pharmaceutically acceptable salts include but are not limited to iodide, isothiocyanate, lactate, lactobionate, laurate, malate, maleate, mandelate, methanesulfonate, methyl bromide, methyl nitrate, methyl sulfate, mucate, naphthenate, nitrate, N-methylglucosamine ammonium salt, 3-hydroxy-2-naphthoate, oleate, oxalate, palmitate, pamoate (1,1-methylene-bis-2-hydroxy-3-naphthoate, einbonate), pantothenate, phosphate / diphosphate, picrate, polygalacturonate, propionate, p-toluenesulfonate, salicylate, stearate, subacetate, succinate, sulfate, sulfosalicylate, suramate, tannate, tartrate, teoclate, toluenesulfonate, triethiodide, and valerate. Pharmaceutically acceptable salts may have more than one charged atom in their structure. In this case, the pharmaceutically acceptable salt may have multiple counterions.Thus, the pharmaceutically acceptable salt may have one or more charged atoms and / or one or more counterions.
[0034] Standard abbreviations for chemical groups well known in the art are used; for example, Me = methyl, Et = ethyl, i-Pr = isopropyl, Bu = butyl, t-Bu = tert-butyl, Ph = phenyl, Bn = benzyl, Ac = acetyl, Bz = benzoyl, etc.
[0035] "Alkyl" refers to a straight or branched chain hydrocarbon group containing 1 to about 20 carbon atoms. For example, the alkyl group can have 1 to 10 carbon atoms or 1 to 6 carbon atoms. Exemplary alkyl groups include straight chain alkyl groups such as methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl, etc., and also include branched chain isomers of straight chain alkyl groups, such as, but not limited to:
[0036] -CH(CH3)2, -CH(CH3)(CH2CH3), -CH(CH2CH3)2, -C(CH3)3, -C(CH2CH3)3, -CH2CH(CH3)2, -CH2CH(CH3)(CH2CH3), -CH2CH(CH2CH3)2 , -CH2C(CH3)3, -CH2C(CH2CH3)3, -CH(CH3)CH(CH3)(CH2CH3), -CH2CH2CH(CH3)2, -CH2CH2CH(CH3)(CH2CH3), -CH2CH2CH(CH2CH3)2 , -CH2CH2C(CH3)3, -CH2CH2C(CH2CH3)3, -CH(CH3)CH2CH(CH3)2, -CH(CH3)CH(CH3)CH(CH3)2, and the like. Thus, alkyl groups include primary, secondary, and tertiary alkyl groups. Alkyl groups may be unsubstituted or optionally substituted with one or more substituents as described herein.
[0037] The term "alkoxy" refers to an -O-alkyl group having a specified number of carbon atoms. For example, (C1-C6)alkoxy includes -O-methyl, -O-ethyl, -O-propyl, -O-isopropyl, -O-butyl, -O-sec-butyl, -O-tert-butyl, -O-pentyl, -O-isopentyl, -O-neopentyl, -O-hexyl, -O-isohexyl and -O-neohexyl.
[0038]
[0043] Unless otherwise stated, the terms "halo" or "halogen" or "halide" by themselves or as part of another substituent mean a fluorine, chlorine, bromine, or iodine atom, preferably fluorine, chlorine or bromine.
[0039] "Haloalkyl" includes monohaloalkyl, polyhaloalkyl, wherein all halogen atoms may be the same or different, and perhaloalkyl, wherein all hydrogen atoms are replaced by the same or different halogen atoms, such as fluorine and / or chlorine atoms. Some examples of haloalkyl include trifluoromethyl, 1,1-dichloroethyl, 1,2-dichloroethyl, 1,3-dibromo-3,3-difluoropropyl, perfluorobutyl, and the like.
[0040] Aryl is a cyclic aromatic hydrocarbon that contains no heteroatoms in the ring. As is well known in the art, aromatic compounds are polyunsaturated ring systems containing 4n+2π electrons (where n is an integer). Thus, aryl includes, but is not limited to: phenyl, azulenyl, heptalenyl, biphenyl, indacenyl, fluorenyl, phenanthrenyl, triphenylenyl, pyrenyl, naphthacenyl, In some embodiments, the aryl group comprises about 6 to about 14 carbons in the ring portion of the group. As defined above, the aryl group can be unsubstituted or substituted. Representative substituted aryl groups can be monosubstituted or substituted more than once, such as, but not limited to, 2-, 3-, 4-, 5-, or 6-substituted phenyl or 2 to 8 substituted naphthyl, which can be substituted by carbon or non-carbon groups such as those listed above.
[0041] Heterocyclyl or the term "heterocyclyl" includes aromatic and non-aromatic ring compounds containing 3 or more ring members, wherein one or more ring atoms are heteroatoms, such as but not limited to N, O and S. Therefore, the heterocyclyl can be a cycloheteroalkyl or heteroaryl, or if it is polycyclic, it can be any combination thereof. In some embodiments, the heterocyclyl contains 3 to about 20 ring atoms, while other such groups have 3 to about 15 ring atoms. The heterocyclyl represented as a C2-heterocyclyl can be a 5-ring with two carbon atoms and three heteroatoms, a 6-ring with two carbon atoms and four heteroatoms, etc. Similarly, a C4-heterocyclyl can be a 5-ring with one heteroatom, a 6-ring with two heteroatoms, etc. The sum of the number of carbon atoms plus the number of heteroatoms is equal to the total number of ring atoms. The size of the ring can also be represented by the total number of atoms in the ring counting both carbon and non-carbon ring atoms, such as 3 to 10 yuan heterocyclyl. The heterocyclyl ring can also contain one or more double bonds. Heteroaryl ring is an embodiment of heterocyclyl. The term "heterocyclyl" includes fused ring species, including those containing fused aromatic and non-aromatic groups. For example, both the dioxolanyl ring and the benzodioxolanyl ring system (methylenedioxyphenyl ring system) are heterocyclyls within the meaning herein. The term also includes polycyclic rings such as bicyclic and tricyclic systems containing one or more heteroatoms, such as, but not limited to, quinuclidine. A heterocyclyl group may be unsubstituted or may be substituted.
[0042] Heteroaryl is a heterocyclic aromatic ring compound containing 5 or more ring members, one or more of which is a heteroatom, such as but not limited to N, O and S; for example, a heteroaryl ring may have 5 to about 8 to 12 ring members. Heteroaryl is a variety of heterocyclic radicals with an aromatic electronic structure, which is a polyunsaturated ring system containing 4n+2π electrons, where n is an integer. The heteroaryl represented by C2-heteroaryl can be a 5-ring (i.e., a 5-membered ring) with two carbon atoms and three heteroatoms, a 6-ring (i.e., a 6-membered ring) with two carbon atoms and four heteroatoms, etc. Similarly, C4-heteroaryl can be a 5-ring with one heteroatom, a 6-ring with two heteroatoms, etc. The sum of the number of carbon atoms plus the number of heteroatoms is equal to the total number of ring atoms. Heteroaryl is also intended to include oxidized S or N, such as sulfinyl, sulfonyl, and N oxides of tertiary ring nitrogen. Carbon or heteroatoms are the connection points of the heteroaryl ring structure, thereby producing a stable compound. Examples of heteroaryl groups include, but are not limited to, pyridyl, pyridazinyl, pyrazinyl, quinoxalinyl, indolizinyl, benzo[b]thienyl, quinazolinyl, purinyl, indolyl, quinolinyl, pyrimidinyl, pyrrolyl, pyrazolyl, Azolyl, thiazolyl, thienyl, iso Azolyl, The heteroaryl group may be unsubstituted or optionally substituted with one or more substituents as described herein.
[0043] Examples of heteroaryl ring systems described herein include structural units of the formula:
[0044]
[0045] Imidazolyl-pyridazines, which may also be described as:
[0046]
[0047] Similarly, other aryl (eg, phenyl) and heteroaryl (eg, pyridinyl) ring systems described herein may be written with explicit double bonds or using aryl "circle" nomenclature, but the meaning is the same.
[0048] Cycloalkyl is a group comprising one or more carbocyclic rings, including but not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl. In some embodiments, cycloalkyl may have 3 to about 8 to 12 ring members, and in other embodiments, the number of ring carbon atoms is 3 to 4, 5, 6 or 7. Cycloalkyl also includes polycyclic cycloalkyl, such as but not limited to norbornyl, adamantyl, bornyl, camphenyl, isocamphenyl and carenyl, and condensed rings, such as but not limited to decanyl (decanlinyl) etc. Cycloalkyl also includes rings substituted with straight or branched alkyl as defined above.
[0049] Cycloalkenyl includes cycloalkyl with at least one double bond between two carbons. Thus for example, cycloalkenyl includes but is not limited to cyclohexenyl, cyclopentenyl and cyclohexadienyl. Cycloalkenyl can have 3 to about 8 to 12 ring members, and in other embodiments, the number of ring carbon atoms is 3 to 5, 6 or 7. Cycloalkyl also includes polycyclic cycloalkyl, such as but not limited to norbornyl, adamantyl, bornyl, camphenyl, isocamphenyl and carenyl, and condensed rings, such as but not limited to decalinyl etc., provided that they contain at least one double bond in the ring. Cycloalkenyl also includes rings substituted with straight or branched alkyl as defined above.
[0050] One or more optional substituents on any group described herein are independently selected from: R A , OR A , halogen, -N=NR A NR A R B 、-(C1-C6-alkyl)NR A R B 、-C(O)OR A 、-C(O)NR A R B 、-OC(O)R A and CN. R A and R B Independently selected from: H, -CN, -hydroxy, oxo, C1-C6-alkyl, C1-C6-alkoxy, C2-C6-alkenyl, C2-C6-alkynyl, NH2, -S(O) 0-2 -(C1-C6-alkyl), -S(O) 0-2 -(C6-C 10 -aryl), C(O)(C1-C6-alkyl), -C(O)(C3-C 14 -Carbocyclic), -C3-C 14 -Carbocyclic group, -(C1-C6-alkyl) (C3-C 14 -Carbocyclic), C6-C 10 -aryl, 3- to 14-membered heterocycloalkyl and -(C1-C 6-alkyl)-(3- to 14-membered heterocycloalkyl) (wherein 1 to 4 heterocycloalkyl members are independently selected from N, O and S), and 5- to 10-membered heteroaryl (wherein 1 to 4 heteroaryl members are independently selected from N, O and S). A and R B Each alkyl, alkoxy, alkenyl, alkynyl, aryl, carbocyclyl, heterocycloalkyl and heteroaryl moiety is optionally substituted with one or more substituents selected from hydroxy, halogen, -NR'2 (wherein each R' is independently selected from C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C6-C 10 -aryl, 3- to 14-membered heterocycloalkyl and -(C1-C6-alkyl)-(3- to 14-membered heterocycloalkyl) (wherein 1 to 4 ring members are independently selected from N, O and S), and 5- to 10-membered heteroaryl (wherein 1 to 4 heteroaryl members are independently selected from N, O and S), -NHC(O)(OC1-C6-alkyl), -NO2, -CN, oxo, -C(O)OH, -C(O)O(C1-C6-alkyl), -C1-C6-alkyl(C1-C6-alkoxy), -C(O)NH2, C1-C6-alkyl, -C(O)C1-C6-alkyl, -OC1-C6-alkyl, -Si(C1-C6-alkyl)3, -S(O) 0-2 -(C1-C6-alkyl), C6-C 10 -aryl, -(C1-C6-alkyl)(C6-C 10 -aryl), 3- to 14-membered heterocycloalkyl and -(C1-C6-alkyl)-(3- to 14-membered heterocycle) (wherein 1 to 4 heterocycle members are independently selected from N, O and S) and -O(C6-C 14 -aryl). Each of the above alkyl, alkenyl, aryl and heterocycloalkyl is optionally substituted with one or more substituents selected from hydroxy, -OC1-C6-alkyl, halogen, -NH2, -(C1-C6-alkyl)NH2, C(O)OH, CN and oxo.
[0051] The compounds described herein may exist in a variety of isomeric forms, including configurational isomers, geometric isomers and conformational isomers, including, for example, cis or trans conformations. The compounds may also exist in one or more tautomeric forms, including single tautomers and mixtures of tautomers. The term "isomer" is intended to encompass all isomeric forms of the compounds of the present disclosure (including tautomeric forms of the compounds). The compounds of the present disclosure may also exist in open chain or cyclized forms. In some cases, one or more of the cyclized forms may be produced by dehydration. The specific composition of the open chain and cyclized forms may depend on how to separate, store or apply the compound. For example, the compound may exist primarily in an open chain form under acidic conditions, and may cyclize under neutral conditions. All forms are included in the present disclosure.
[0052] The substituent -CO2H can be substituted by a bioisosteric substituent, for example:
[0053]
[0054] etc., where R has the same meaning as defined herein. A Same definition. See, for example, THE PRACTICE OF MEDICINAL CHEMISTRY (Academic Press: New York, 1996), p. 203.
[0055] Some compounds described herein may have asymmetric centers and therefore exist in different enantiomers and diastereoisomers. Compounds as described herein may be in the form of optical isomers or diastereomers. Therefore, the present disclosure encompasses compounds and uses thereof in the form of optical isomers, diastereomers, and mixtures thereof (including racemic mixtures) as described herein. The optical isomers of compounds of the present disclosure may be obtained by known techniques such as asymmetric synthesis, chiral chromatography, simulated moving bed technology, or by chemical separation of stereoisomers using optically active resolving agents.
[0056] Unless otherwise indicated, the term "stereoisomer" means one stereoisomer of a compound that is substantially free of other stereoisomers of the compound. Therefore, a stereoisomerically pure compound with one chiral center will be substantially free of the opposite enantiomer of the compound. A stereoisomerically pure compound with two chiral centers will be substantially free of other diastereomers of the compound. A typical stereoisomerically pure compound contains greater than about 80% by weight of one stereoisomer of the compound and less than about 20% by weight of other stereoisomers of the compound, such as greater than about 90% by weight of one stereoisomer of the compound and less than about 10% by weight of other stereoisomers of the compound, or greater than about 95% by weight of one stereoisomer of the compound and less than about 5% by weight of other stereoisomers of the compound, or greater than about 97% by weight of one stereoisomer of the compound and less than about 3% by weight of other stereoisomers of the compound, or greater than about 99% by weight of one stereoisomer of the compound and less than about 1% by weight of other stereoisomers of the compound. The stereoisomers described above can be viewed as compositions comprising both stereoisomers present in their respective weight percentages as described herein.
[0057] If there is a discrepancy between the structure shown and the name given to that structure, the structure shown shall prevail. In addition, if the stereochemistry of a structure or portion of a structure is not indicated, for example, in bold or dashed, the structure or portion of a structure should be interpreted as encompassing all stereoisomers thereof. However, in some cases, where there is more than one chiral center, the structure and name may be indicated as a single enantiomer to help describe the relative stereochemistry. One skilled in the art of organic synthesis will know whether a compound is prepared as a single enantiomer by the process used to prepare it.
[0058] As used herein, and unless otherwise indicated to the contrary, the term "compound" is inclusive in that it encompasses a compound or a pharmaceutically acceptable salt, stereoisomer, and / or tautomer thereof. Thus, for example, a compound of Formula (I), Formula (IA), or Formula (II) includes pharmaceutically acceptable salts of tautomers of the compound.
[0059] Compound
[0060] The present disclosure provides, in various embodiments, compounds of Formula (IA) or Formula (II), or pharmaceutically acceptable salts thereof:
[0061]
[0062] In formula (IA), X is S, -N=C(R 1 )-, or-C(R 1 )=C(R 1 )-.
[0063] In some embodiments, the compound is a compound of formula (IA). In other embodiments, the compound is a compound of formula (II).
[0064] The present disclosure provides, in various embodiments, optionally in combination with any other embodiments described herein, as a compound of formula (I), a compound of formula (IA) or a pharmaceutically acceptable salt thereof:
[0065]
[0066] X is S, -N=C(R 1 )-, or-C(R 1 )=C(R 1 )-;R 1 Each is independently H, F, Cl, C1-C6-alkyl, vinyl or ethynyl (both of which may be substituted), cyano, alkoxy or haloalkyl.
[0067] R 2is selected from: -C(O)OR, -C(O)NH(C1-C6-alkyl) (wherein the alkyl is optionally substituted), optionally substituted C3-C6-cycloalkenyl, and 3- to 10-membered heterocyclyl. For example, in some embodiments optionally combined with any other embodiments described herein, R 2 It is -C(O)OR.
[0068] R is selected from the group consisting of: H, alkyl optionally substituted with -((C1-C6-alkyl)OC(O)OC1-C6-alkyl) or 3- to 10-membered heterocyclyl, and benzyl, wherein the benzyl may be unsubstituted or substituted with methoxy or with an acid or ester isostere. In various embodiments, R is H, alkyl, or benzyl, wherein the benzyl may be unsubstituted or substituted with methoxy or with an acid or ester isostere.
[0069] Ring A is a 5- or 6-membered heteroaryl group containing 1, 2 or 3 N atoms, unsubstituted or substituted with 1, 2 or 3 groups independently selected from the group consisting of NH2, NH-benzyl (wherein the benzyl group is unsubstituted or substituted with methoxy, cyano, alkylnitrile, haloalkyl, hydroxymethyl, aminomethyl, aminopropyl, carboxamido or alkoxy),
[0070]
[0071] The wavy lines indicate bonding locations.
[0072] In various embodiments, Ring A comprises any of pyridazinyl, triazolyl, pyrimidinyl, and pyridinyl, any of which may be unsubstituted or substituted as described herein.
[0073] In other embodiments, the disclosure provides specific examples of compounds and pharmaceutically acceptable salts thereof, as shown below in Table 1. The compounds are presented with activity scores and physicochemical characterization data derived in part from the ISG-LUC activation assay as described herein.
[0074] Table 1: Specific compounds and activity scores. Activity scores are based on potency and efficacy data (+ = EC 50 >20,000 nM; ++ = active, but less potent and less effective than reference compound (EC 50 >1000 nM; +++ = activity comparable to that of the reference compound (EC 50 <3000 nM)); ++++ = higher potency and efficacy than reference compound (EC 50 <900nM)).
[0075]
[0076]
[0077]
[0078]
[0079]
[0080]
[0081]
[0082]
[0083]
[0084]
[0085]
[0086]
[0087]
[0088]
[0089]
[0090]
[0091]
[0092]
[0093]
[0094]
[0095]
[0096]
[0097]
[0098]
[0099]
[0100]
[0101]
[0102]
[0103]
[0104]
[0105] Related references
[0106] [1]Corrales L, Glickman LH, McWhirter SM, Kanne DB, Sivick KE, Katibah GE, Woo SR, Lemmens E, Banda T, Leong JJ, Metchette K, Dubensky TW Jr, Gajewski TF. (2015) Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity. Cell Rep. 11: 1018 - 30.
[0107] [2]Deng, L. et al. (2014) STING - Dependent Cytosolic DNA Sensing Promotes Radiation - Induced Type I Interferon - Dependent Antitumor Immunity in Immunogenic Tumors, Immunity. 41: 843.
[0108] [3]Corrales L, Matson V, Flood B, Spranger S, Gajewski TF. (2017) Innate immune signaling and regulation in cancer immunotherapy. Cell Res. 27: 96 - 108.
[0109] [4]Corrales L, McWhirter SM, Dubensky TW Jr, Gajewski TF. (2016) The host STING pathway at the interface of cancer and immunity. J Clin Invest. 126: 2404 - 11.
[0110] How to use
[0111] The present disclosure also provides, in one embodiment, a method for stimulating the expression of an interferon gene in a human patient. The method comprises administering to the patient an effective dose of a compound as described herein or a pharmaceutically acceptable salt thereof.
[0112] In another embodiment, the present disclosure provides a method for treating a tumor in a patient. The method comprises administering to the patient an effective dose of a compound or a pharmaceutically acceptable salt thereof.
[0113] With respect to combination therapies comprising administration of a compound of the disclosure and an immune checkpoint targeting drug, or as a combination therapy for enhancing ionizing radiation-based and existing chemotherapeutic therapeutic approaches (e.g., DNA damage-based chemotherapy), the STING agonists of the disclosure may complement and enhance the effects of these known treatments. This is based on recent papers demonstrating a key role for STING-dependent micronucleus-mediated tumor clearance using these approaches, see, e.g.,
[0114] [5] Mackenzie, KF, et all, (2017), cGAS surveililance of micronucleilinks genome instability to innate immunity, Nature, 548, 461.
[0115] [6] Wang, W. et al., (2016), Effector T Cells Abrogate Stroma-MediatedChemoresistance in Ovarian Cancer, Cell, 165, 1092-1105.
[0116] [7] Charlotte E. Ariyan, et al., January 16, 2018; DOI: 10.1158 / 2326-6066, Robust antitumor responses result from local chemotherapy and CTLA-4blockade, cancerimmunolres.aacrjournals.org on January 31, 2018.
[0117] [8] Chung Kil Song, et al., www.moleculartherapy.org vol, 15 no.8aug.2007, Chemotherapy Enhances CD8+ T Cell-mediated Antitumor ImmunityInduced by Vaccination With Vaccinia Virus.
[0118] The compounds of the present disclosure can be used in combination with an effective dose of an immune checkpoint targeted drug. For example, the immune checkpoint targeted drug can be an anti-PD-L1 antibody, an anti-PD-1 antibody, an anti-CTLA-4 antibody, or an anti-4-1BB antibody. See, for example:
[0119] [9] Ager, CR, et al., (2017) Cancer Immunol Res; 5(8), 676.
[0120]
[10] Fu, J. et al. (2015) Sci Transl Med.2015 April 15;7(283):283ra52.doi:10.1126 / scitranslmed.aaa4306.
[0121]
[11] Wang, H., et al. (2017) PNAS, February 14, 2017, vol.114, no.7, 1637-1642.
[0122] Pharmaceutical composition
[0123] In another embodiment, the present disclosure provides a pharmaceutical composition comprising a compound as described herein or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or excipient.
[0124] The compositions of the present disclosure may be administered orally, topically, parenterally, by inhalation or spray, or rectally in dosage unit formulations. The term parenteral as used herein includes subcutaneous injections, intravenous, intramuscular, intrasternal injection or infusion techniques.
[0125] Suitable oral compositions as described herein include, but are not limited to, tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, syrups or elixirs.
[0126] Compositions of the present disclosure suitable for oral use can be prepared according to any method known in the art for manufacturing pharmaceutical compositions. For example, liquid formulations of compounds of the present disclosure include one or more agents selected from sweeteners, flavoring agents, coloring agents, and preservatives to provide pharmaceutically acceptable (palatable) formulations of the compound or its pharmaceutically acceptable salt.
[0127] For tablet compositions, the compound or its pharmaceutically acceptable salt mixed with a non-toxic pharmaceutically acceptable excipient is used to make a tablet. Examples of such excipients include, but are not limited to: inert diluents such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrants such as corn starch or alginic acid; binders such as starch, gelatin or gum arabic; and lubricants such as magnesium stearate, stearic acid or talc. Tablets may be uncoated or coated by known coating techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained therapeutic effect over a desired period of time. For example, a time-delay material such as glyceryl monostearate or glyceryl distearate may be used.
[0128] Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent such as calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium such as peanut oil, liquid paraffin or olive oil.
[0129] For aqueous suspensions, the compound or a pharmaceutically acceptable salt thereof is mixed with an excipient suitable for maintaining a stable suspension. Examples of such excipients include, but are not limited to, sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, tragacanth gum, and gum arabic.
[0130] Oral suspensions may also include dispersants or wetting agents, such as naturally occurring phosphatides, such as lecithin, or condensation products of alkylene oxides with fatty acids, such as polyoxyethylene stearate, or condensation products of ethylene oxides with long-chain aliphatic alcohols, such as 17-carbon ethyleneoxy hexadecanol, or condensation products of ethylene oxides with partial esters derived from fatty acids and hexitol, such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxides with partial esters derived from fatty acids and hexitol anhydrides, such as polyethylene sorbitan monooleate. Aqueous suspensions may also contain one or more preservatives, such as ethyl or n-propyl p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweeteners (such as sucrose or saccharin).
[0131] Oily suspensions can be prepared by suspending the compound or its pharmaceutically acceptable salt in a vegetable oil (e.g., peanut oil, olive oil, sesame oil or coconut oil) or a mineral oil (e.g., liquid paraffin). The oily suspensions may contain a thickening agent such as beeswax, hard paraffin or cetyl alcohol.
[0132] Sweetening agents such as those set forth above, and flavoring agents may be added to provide an acceptable oral preparation. These compositions may be preserved by the addition of an antioxidant such as ascorbic acid.
[0133] Dispersible powders and granules suitable for preparing aqueous suspensions by adding water provide the compound or a pharmaceutically acceptable salt thereof mixed with a dispersant or wetting agent, a suspending agent and one or more preservatives. Suitable dispersants or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients such as sweeteners, flavoring agents and coloring agents may also be present.
[0134] The pharmaceutical composition of the present disclosure may also be in the form of an oil-in-water emulsion. The oil phase may be a vegetable oil, such as olive oil or peanut oil, or a mineral oil, such as liquid paraffin, or a mixture of these. Suitable emulsifiers may be naturally occurring gums, such as gum arabic or tragacanth; naturally occurring phospholipids, such as soybean, lecithin; and esters or partial esters derived from fatty acids and hexitol anhydrides, such as sorbitan monooleate and condensation products of the partial esters with ethylene oxide, such as polyoxyethylene sorbitan monooleate. The emulsion may also contain sweeteners and flavoring agents.
[0135] Syrups and elixirs can be prepared with sweeteners (e.g., glycerol, propylene glycol, sorbitol, or sucrose). Such preparations may also contain demulcents, preservatives, and flavoring and coloring agents. Pharmaceutical compositions may be in the form of sterile injectables, aqueous suspensions, or oily suspensions. The suspensions may be prepared according to known techniques using those suitable dispersants or wetting agents and suspending agents already mentioned above. Sterile injectable preparations may also be sterile injectable solutions or suspensions in nontoxic, parent-acceptable diluents or solvents, such as solutions in 1,3-butanediol. Acceptable carriers and solvents that may be used include water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile fixed oils are typically used as solvents or suspension media. For this purpose, any mild fixed oil may be used, including synthetic monoglycerides or diglycerides. In addition, it has been found that fatty acids such as oleic acid may be used in the preparation of injectables.
[0136] Compounds or pharmaceutically acceptable salts thereof can also be administered in the form of suppositories for rectal administration. These compositions can be prepared by mixing the compound with a suitable non-irritating excipient that is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the compound. Exemplary excipients include cocoa butter and polyethylene glycols.
[0137] Compositions for parenteral administration are administered in a sterile medium. Depending on the carrier used and the concentration of the compound or its pharmaceutically acceptable salt in the formulation, the parenteral formulation can be a suspension or a solution containing the dissolved compound. Excipients such as local anesthetics, preservatives and buffers can also be added to the parenteral composition. Example
[0138] The following non-limiting examples are intended to illustrate additional embodiments of the present disclosure.
[0139] Tissue culture. Wild-type (Catalog No. thpl-isg) and STING KO (Catalog No. thpd-kostg) THP-1-Lucia ISG cells were purchased from Invivogen and maintained in growth medium consisting of RPMI 1640, 2 mM L-glutamine, 25 mM HEPES, 10% heat-inactivated fetal bovine serum (FBS), 1,000 units / ml penicillin, 1,000 μg / ml streptomycin, 0.25 μg / ml amphotericin B, and 100 μg / ml zeocin, unless otherwise stated.
[0140] Type 1 interferon stimulation. poly(dA:dT) and 2'3'-cGAMP were purchased from invivogen and resuspended according to the manufacturer's instructions.
[0141] ISRE-luciferase assay. THP-1Lucia ISG cells were cultured at 5×10 5 Cells were resuspended in low serum growth medium (2% FBS) at a density of 10 cells / ml and treated with the test article or vehicle (DMSO). 50 μL of cells were inoculated into each well of a 384-well white greiner plate and incubated for 24 hours. To evaluate the expression of the luciferase reporter gene, 30 μL of Quanti-luc (Invivogen) detection reagent was added to each well and luminescence was read using an Envision plate reader (Perkin Elmer) with an integration time set to 0.1 seconds.
[0142] Viability assay. Cells were plated at 5×10 5Cells were resuspended in low serum growth medium at a density of 10 cells / ml and treated with the test article or vehicle (DMSO). 50 μL of cells were inoculated into each well of a 384-well white Grena plate and incubated for 24 hours. To evaluate the expression of the luciferase reporter, 30 μl of CellTiter-Glo (Promega) detection reagent was added to each well and luminescence was detected using an Envision plate reader with an integration time set to 0.1 seconds.
[0143] Western blotting. Cells were lysed in 1× protein lysis buffer (25 mM HEPES, pH 7.4, 300 mM NaCl, 1.5 mM MgCl2, 1 mM EGTA, 1% P-40, 1% sodium deoxycholate, 2.5 mM sodium pyrophosphate, 1 mM glycerophosphate) freshly supplemented with protease and phosphatase inhibitors (Cell Signaling). TM 4 to 12% Bis-Tris Gel and Bolt TM Western blotting was performed using the microtransfer system according to the manufacturer's instructions (ThermoFisher Scientific). STING and γ-tubulin antibodies were purchased from Cell Signaling and diluted in 5% BSA, 1× TBS-T buffer (Table 3). Anti-rabbit HRP antibody was diluted in 5% nonfat dry milk, 1× TBS-T buffer, and the luminescent signal was imaged using ChemiDocImager (BioRad).
[0144] Semi-quantitative real-time PCR (qPCR). THP-1 cells were cultured at 5×10 5 The density of individual cells / ml was resuspended in low serum growth medium and treated with the test product or vehicle (DMSO). 2.5mL cells were inoculated into each well of a 6-well plate and incubated for 24 hours. RNA was isolated using RNeasy Plus Mini Kit (Qiagen), and 1 μg of purified RNA was reverse transcribed into cDNA (VILO, catalog number 11755050, ThermoFisher Scientific). Taqman primers and probes listed in Table 4 were used to assess gene expression according to the manufacturer's instructions using Taqman Universal Mix II (catalog number 4440038, ThermoFisher). Gene expression was normalized using the double ΔCt method and reported with expression fold changes.
[0145] STING Thermal Shift Assay (TSA). The c-terminal domains (CTD) of human and mouse STING were expressed and purified as previously described (Ouyang, S., Song, X., Wang, Y., Ru, H., Shaw, N., Jiang, Y., Niu, F., Zhu, Y., Qiu, W., Parvatiyar, K., et al. (2012). Structural analysis of the STING adaptor protein reveals a hydrophobic dimer interface and mode of cyclic di-GMP binding. Immunity 36, 1073-1086.). Test articles or vehicle controls were added to diluted STING protein (0.22 mg / ml) in 1× protein thermal shift buffer (provided in the Protein Thermal Shift Dye Kit (Cat. No. 4461146, ThermoFisher Scientific)). The thermal shift dye was added and mixed, and a melting curve was performed according to the parameters outlined for the dye kit. Melting temperatures (Tm) were calculated using the Protein Thermal Shift Software v1.3 (Cat. No. 4466038, ThermoFisher Scientific) using the derivative method.
[0146] WT STING Binding Assay (Cisbio, Catalog No. 64BDSTGPEH). The assay format was optimized to demonstrate binding of the natural ligand, 2'3'cGAMP labeled with d2 (acceptor), to recombinant 6×His-tagged human STING protein labeled with Terbium Cryptate. When the two dyes are in proximity, a flash lamp on the PHERAstar FSX plate reader excites the donor triggering Fluorescence Resonance Energy Transfer (FRET) toward the acceptor, which in turn fluoresces at 665nm. To evaluate the ability of synthetic small molecule STING ligands to bind to human STING, a competitive assay format was employed. A 10-point titration of 5uL of each synthetic ligand was transferred to a 384-well plate, and then 20uL of assay buffer containing 6×His-tagged human STING protein and labeled 2'3'cGAMP ligand was transferred to a 384-well plate and incubated for 3 hours at room temperature. The raw values obtained from PHERAstar were used to calculate the reported IC by curve fitting in Genedata 50 Values (signal is inversely proportional to binding of synthetic ligand). Percent inhibition was calculated based on maximal binding of synthetic compounds relative to maximal binding of unlabeled 2'3' cGAMP, which was used as a control in each assay.
[0147] Table 2: Cell signaling antibodies
[0148] Protein Targets Catalog Number dilution STING 13647 1:1000 γ-Tubulin 5886 1:3000 Rabbit IgG 7074 1:3000
[0149] Table 3: ThermoFisher Scientific Taqman Primers / Probes
[0150]
[0151]
[0152] Compounds useful in practicing the methods of the present disclosure can be prepared according to the following steps, combined with common knowledge and skills of organic synthesis, substituting appropriate reagents, as will be apparent to the practitioner.
[0153] Experimental procedures
[0154] Abbreviations. The following abbreviations are used: tetrahydrofuran (THF), dichloromethane (DCM), N,N-dimethylformamide (DMF), dimethylacetamide (DMA), dimethyl sulfoxide (DMSO), trifluoroacetic acid (TFA), triethylamine (TEA), diisopropylethylamine (DIPEA), (1-cyano-2-ethoxy-2-oxoethylideneaminooxy)dimethylamino-morpholino-carbonyl) Hexafluorophosphate (COMU), 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridine 3-oxide hexafluorophosphate, N-[(dimethylamino)-1H-1,2,3-triazolo[4,5-b]pyridin-1-ylmethylene]-N-methylformamide Hexafluorophosphate N-oxide (N-[(dimethylamino)-1H-1,2,3-triazolo-[4,5-b]pyridin-1-ylmethylene]-N-methylmethanaminium hexafluorophosphate N-oxide) (HATU).
[0155] General examples for preparing compounds of the present disclosure. The starting materials and intermediates of compounds of the present disclosure can be prepared by application or modification of the methods described below, or by obvious chemical equivalents thereof, or for example as described in documents such as The Science of Synthesis, Volumes 1-8. Editors EM Carreira et al. Thieme publishers (2001-2008). Commercial computer search engines such as Scifinder (www.cas.org) or Reaxys (www.reaxys.com) can also be used to obtain the details of reagents and reaction schemes by searching for structures and reactions.
[0156] Part I: Preparation of intermediates
[0157] Scheme 1: Synthesis of Intermediate-A:
[0158]
[0159] Step 1: Synthesis of 6-(pyridin-4-yl)pyridazine-3-carboxylic acid ethyl ester: To an argon-purged solution of 6-chloropyridazine-3-carboxylic acid ethyl ester (4.0 g, 21.4 mmol), 4-(tributylstannyl)pyridine (8.71 g, 23.65 mmol) in 1,4-dioxane (40 mL) was added, and the resulting mixture was stirred at room temperature for 10 minutes, and then Pd(PPh3)4 (2.48 g, 2.15 mmol) was added. The reaction mixture was stirred at 110°C for 16 hours. After completion, the reaction mixture was diluted with a saturated aqueous solution (50 mL) solution of NaHCO3, extracted with EtOAc (30 mL×3), dried with anhydrous Na2SO4, filtered and concentrated under reduced pressure. The resulting residue was purified by column chromatography to obtain 6-(pyridin-4-yl)pyridazine-3-carboxylic acid ethyl ester (2.5 g, 46% yield) as a white solid.
[0160] 1 H NMR (400MHz, DMSO-d6): δ8.84 (m, 2H), 8.58 (d, J=8.8Hz, 1H), 8.38 (d, J=8.8Hz, 1H), 8. 21 (m, 2H), 4.48 (q, J=7.2Hz, 2H), 1.40 (t, J=7.2Hz, 3H). LC-MS (ESI+): mz; 230.14[M+H] + .
[0161] Step 2: Synthesis of 6-(pyridin-4-yl)pyridazine-3-carboxylic acid (A): An aqueous solution of lithium hydroxide monohydrate (0.55 g, 13.1 mmol) in water (10 mL) was added to a solution of 6-(pyridin-4-yl)pyridazine-3-carboxylic acid ethyl ester (2.5 g, 10.9 mmol) in THF (10 mL) at 0°C, and the resulting mixture was stirred at room temperature for 5 hours. MeOH (10 mL) was added and the mixture was stirred at 60°C for 1 hour. After the reaction was complete, THF and MeOH were removed under reduced pressure, and the water layer was acidified with 2N HCl (pH-4). The resulting solid was filtered, washed with water and dried. Then, it was ground with acetonitrile, filtered, and the filter cake was dried to obtain compound A (1.4 g, 53% yield) as a light brown solid.
[0162] 1 H NMR (400MHz, DMSO-d6): δ14.02 (s, 1H), 8.84 (m, 2H), 8.56 (d, J=8.8Hz, 1H), 8.36 (d, J=8.8Hz, 1H), 8.21 (m, 2H). LC-MS (ESI-): m / z; 200.11[MH] - .
[0163] Scheme 2: Synthesis of Intermediate-B:
[0164]
[0165] Step 1: Synthesis of 6-(1H-pyrazol-4-yl)pyridazine-3-carboxylic acid ethyl ester: Argon is purged through a solution of pyrazole-4-boric acid (4.51 g, 40.31 mmol), NaCO (7.1 g, 67.2 mmol) and 6-chloropyridazine-3-carboxylic acid ethyl ester (5 g, 26.88 mmol) in 1,4-dioxane (175 mL) and water (25 mL) for 10 minutes, then Pd(PPh) (1.55 g, 1.34 mmol) is added. The reaction mixture is stirred at 90 ° C for 1 hour. After the reaction is complete, it is cooled to room temperature and diluted with EtOAc (250 mL). It is then washed with water (100 mL), brine (100 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by column chromatography over silica gel to give 3.2 g of ethyl 6-(1H-pyrazol-4-yl)pyridazine-3-carboxylate as an off-white solid. LC-MS (ESI+): m / z; 219.0 [M+H]+.
[0166] Step 2: Synthesis of ethyl 6-(1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-yl)pyridazine-3-carboxylate:
[0167] At 0 ℃, NaH (60% w / w) (0.422g, 17.6mmol) is added to the stirring solution of 6- (1H- pyrazoles -4- bases) pyridazine -3- carboxylic acid ethyl ester (3.2g, 14.67mmol) in THF (64mL) and DMF (30mL) in batches and stirred for 10 minutes. SEM-Cl (2.93g, 17.61mmol) is added thereto and the reaction mixture is stirred at 0 ℃ for 30 minutes. Then it is quenched with 10% citric acid solution, and the solid thus obtained is filtered, washed with water (5mL × 2) and dried. The residue is purified by column chromatography through silica gel (using 0 to 5% methanol in dichloromethane as eluent), to obtain 6- (1- ((2- (trimethylsilyl) ethoxy) methyl) -1H- pyrazoles -4- bases) pyridazine -3- carboxylic acid ethyl ester of 2.65g as off-white solid. LC-MS (ESI+): m / z; 349.1 [MH] + .
[0168] Step 3: Synthesis of 6-(1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-yl)pyridazine-3-carboxylic acid (B):
[0169] The aqueous solution (0.382g, 9.13mmol, in 3mL water) of lithium hydroxide monohydrate is added to a solution of 6-(1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole-4-yl)pyridazine-3-carboxylic acid ethyl ester (2.65g, 7.61mmol) in THF (9mL) at 0°C, and stirred at room temperature for 2 hours. After the reaction is complete, the reaction mixture is diluted with water (10mL) and washed with EtOAc (30mL×2). The water layer is acidified with 2N HCl (pH-4) solution, and the solid thus obtained is filtered, washed with water (2mL×2) and dried to obtain 1.1g of B as an off-white solid.
[0170] 1 H NMR (400MHz, DMSO-d6) δ13.62 (s, 1H), 8.78 (s, 1H), 8.33 (s, 1H), 8.18-8.13 (m, 2H), 5. 51 (s, 2H), 3.61 (t, J=8.0Hz, 2H), 0.87 (d, J=8.0Hz, 2H), 0.04 (s, 9H). LC-MS (ESI+): m / z 321.0[M+H] + .
[0171] Scheme 3: Synthesis of Intermediate-C:
[0172]
[0173] Step 1: the synthesis of 6-((trimethylsilyl)ethynyl)pyridazine-3-carboxylic acid methyl esters: to the solution of 6-chloropyridazine-3-carboxylic acid methyl esters (1g, 5.79mmol) in THF (10mL), add ethynyl(trimethyl)silane (4.0mL, 29.0mmol), Pd(PPh ) 2Cl 2 (407mg, 0.58mmol), CuI (221mg, 1.2mmol) and Et 3N (0.807mL, 5.79mmol), and the gained mixture was stirred for 1 hour at 25 ℃.After the reaction was completed, the mixture was filtered through a silica gel pad, and the filtrate was concentrated under reduced pressure. Residue was purified by column chromatography (PE / EtOAc), to obtain 6-((trimethylsilyl)ethynyl)pyridazine-3-carboxylic acid methyl esters (500mg, 37% yield) as a yellow solid.
[0174] Step 2: the synthesis of 6-ethynyl pyridazine-3-carboxylic acid methyl esters: to the solution of 6-((trimethylsilyl)ethynyl)pyridazine-3-carboxylic acid methyl esters (500mg, 2.13mmol) in THF (10mL), TBAF (1M in THF, 4.27mL, 4.27mmol) was added, and the reaction mixture was stirred at room temperature for 1 hour. After completion, the reaction mixture was poured into H2O (50mL) and extracted with DCM (30mL × 3). The organic layer merged was washed with salt water (50mL), Na2SO4 was used, filtered and concentrated under reduced pressure. Residue was purified by column chromatography (PE / EtOAc), to obtain 6-ethynyl pyridazine-3-carboxylic acid methyl esters (260mg, 75% yield) as a brown solid.
[0175] Step 3: Synthesis of 6-(1-(4-methoxybenzyl)-1H-1,2,3-triazol-4-yl)pyridazine-3-carboxylic acid methyl ester: To a solution of 6-ethynylpyridazine-3-carboxylic acid methyl ester (500 mg, 3.1 mmol) and 1-(azidomethyl)-4-methoxy-benzene (1.0 g, 6.2 mmol) in H o (4 mL) and t-BuOH (16 mL) was added CuSO (98.4 mg, 0.62 mmol) and sodium ascorbate (489 mg, 2.5 mmol). The reaction mixture was purged with nitrogen and stirred at 40 ° C for 2 hours. After the reaction was complete, it was diluted with EtOAc (50 mL) and H o (20 mL). The precipitate was filtered and the filter cake was washed with DCM / MeOH 10 / 1 (500 mL). The filtrate was concentrated under reduced pressure to give methyl 6-(1-(4-methoxybenzyl)-1H-1,2,3-triazol-4-yl)pyridazine-3-carboxylate (600 mg, 60% yield) as a grey solid. LCMS (ESI+): m / z 325.9 [M+H] + .
[0176] Step 4: Synthesis of lithium 6-(1-(4-methoxybenzyl)-1H-1,2,3-triazol-4-yl)pyridazine-3-carboxylate (C): To a solution of methyl 6-(1-(4-methoxybenzyl)-1H-1,2,3-triazol-4-yl)pyridazine-3-carboxylate (250 mg, 0.77 mmol) in THF (2.5 mL) at 0°C was added a solution of lithium hydroxide monohydrate (96.7 mg, 2.3 mmol) in water (2.5 mL). After stirring at room temperature for 12 hours, the precipitate was filtered and the filter cake was dried under reduced pressure. The residue was triturated with acetonitrile and filtered to give acid C (70.0 mg, 29% yield) as a grey solid. LCMS (ESI+): m / z 312 [M+H] + .
[0177] Part II: Preparation of Example Compounds
[0178] All compounds were prepared using the procedures illustrated below.
[0179] Embodiment 1:
[0180] Scheme 4: Synthesis of compound 1:
[0181]
[0182] Step 1: Synthesis of methyl 5-fluoro-2-(6-(pyridin-4-yl)pyridazine-3-carboxamido)-4-((trimethylsilyl)ethynyl)benzoate:
[0183] At room temperature to the solution of intermediate C (1.4g, 7.0mmol) and DIPEA (6.17mL, 34.8mmol) in DCE (30mL) add T3P (50% in EtOAc) (13.29mL, 20.89mmol), then add 2-amino-5-fluoro-4-((trimethylsilyl) ethynyl) methyl benzoate (1.8g, 7.0mmol).Reaction mixture was stirred 7 hours at 80 ℃.After the reaction was completed, volatiles were removed under reduced pressure and NaHCO3 saturated aqueous solution (15mL).The gained solid was filtered, washed with water and dried.Residue was purified by column chromatography (PE / EtOAc), to obtain 5-fluoro-2-(6-(pyridin-4-yl) pyridazine-3-formamido)-4-((trimethylsilyl) ethynyl) methyl benzoate (2.2g, 70% yield) as a light cream solid.
[0184] 1 H NMR (400MHz, DMSO-d6): δ12.96 (s, 1H), 8.98-8.84 (m, 1H), 8.69 (d, J=8.8Hz, 2H), 8.52 (m, 1H), 8 .26(m, 1H), 8.24(m, 2H), 7.92(m, 1H), 3.97(s, 3H), 0.29(s, 9H).LC-MS(ESI-): m / z; 447.28[MH] - .
[0185] Step 2: Synthesis of methyl 4-ethynyl-5-fluoro-2-(6-(pyridin-4-yl)pyridazine-3-formamido)benzoate: TBAF (1M in THF) (4.9 mL, 4.9 mmol) was added to a stirred solution of 5-fluoro-2-(6-(pyridin-4-yl)pyridazine-3-formamido)-4-((trimethylsilyl)ethynyl)benzoate (2.2 g, 4.90 mmol) in THF (22 mL) at 0°C, and the resulting mixture was stirred at room temperature for 30 minutes. After the reaction was complete, saturated NaHCO3 aqueous solution (20 mL) was added. The solid was filtered, washed with water and dried. The resulting residue was purified by column chromatography (DCM / MeOH) to give methyl 4-ethynyl-5-fluoro-2-(6-(pyridin-4-yl)pyridazine-3-carboxamido)benzoate (1.1 g, 60% yield) as a light orange solid.
[0186] 1 H NMR (400MHz, DMSO-d6): δ12.96 (s, 1H), 8.97 (d, J=6.8Hz, 1H), 8.86-8.84 (m, 2H), 8.68 (d, J=8.8Hz, 1H) , 8.51 (d, J=8.8Hz, 1H), 8.26-8.24 (m, 2H), 7.93 (d, J=10.0Hz, 1H), 4.87 (s, 1H), 3.97 (s, 3H). LCMS: m / z 377.2[M+H] + .
[0187] Step 3: Synthesis of lithium 4-ethynyl-5-fluoro-2-(6-(pyridin-4-yl)pyridazine-3-formamido)benzoate (1): An aqueous solution of lithium hydroxide monohydrate (33.4 mg, 0.8 mmol) in water (2 mL) was added to a solution of methyl 4-ethynyl-5-fluoro-2-(6-(pyridin-4-yl)pyridazine-3-formamido)benzoate (200 mg, 0.5 mmol) in THF (4 mL) at 0° C., and the resulting mixture was stirred at room temperature for 2 hours. After the reaction was complete, the resulting solid was filtered, washed with water and dried. It was then ground with acetonitrile, filtered and dried to obtain compound 1 (99 mg, 54% yield) as a lithium salt as an off-white solid.
[0188] 1H NMR (400MHz, DMSO-d6): δ8.93 (d, J=6.8Hz, 1H), 8.85-8.83 (m, 2H), 8.61 (d, J=8.8Hz, 1H), 8.4 3 (d, J=8.8Hz, 1H), 8.25-8.24 (m, 2H), 7.79 (d, J=10.4Hz, 1H), 4.52 (s, 1H). LC-MS (ESI+): m / z 363.2[M+H] + .
[0189] A procedure analogous to that used to synthesize compound 1 was used to synthesize compounds 10, 13, 16, 19, 38, 44, 49, 52, 29, 31, 33, 46, 47, 77, 54, 53, 57, 58, 63, 66, 60, 55, 56, 46, 79, 66, 67, 68, 69, 70, 71, 73, 96, 97, 98, 99, 100, 101, 102, 103, 104, 107, 108, 10, 90, 82, 88, and 81, etc.
[0190] Embodiment 2:
[0191] Scheme 5: Synthesis of compound 2:
[0192]
[0193] Step 1: Synthesis of tert-butyl ((3,6-dichloropyridazine-4-yl)methyl)carbamate: To a suspension of Boc-glycine (20.0 g, 114.2 mmol) in H2O (100 mL), 3,6-dichloropyridazine (10.0 g, 67.1 mmol) and silver nitrate (1.1 g, 6.7 mmol) were added, and the resulting mixture was heated at 80° C. A solution of ammonium sulfate (27.6 g, 120.9 mmol) in H2O (40 mL) was added dropwise to the reaction mixture at 80° C. over 30 minutes. The reaction mixture was then stirred at 80° C. for another 30 minutes. It was then cooled to room temperature, basified with concentrated ammonium hydroxide (pH 10), and extracted with EtOAc (100 mL×2). The combined organic layers were washed with brine (200 mL), dried over anhydrous Na2SO4, and concentrated under reduced pressure. The residue was purified by column chromatography (hexane / EtOAc) to give tert-butyl ((3,6-dichloropyridazin-4-yl)methyl)carbamate (15.0 g, 40% yield) as a light red thick oil.
[0194] 1H NMR (400MHz, CDCl3): δ7.49 (s, 1H), 4.38 (d, J=6.0Hz, 2H), 1.49 (s, 9H). LC-MS (ESI-): m / z 278.1[MH] - .
[0195] Step 2: Synthesis of tert-butyl ((6-chloro-3-(1H-imidazol-1-yl)pyridazin-4-yl)methyl)carbamate and tert-butyl ((3-chloro-6-(1H-imidazol-1-yl)pyridazin-4-yl)methyl)carbamate: To a solution of imidazole (5.9 g, 86.2 mmol) in THF (200 mL) at 0°C, NaH (60% in mineral oil) (3.5 g, 86.2 mmol) was added, and the resulting mixture was stirred for 15 minutes. tert-butyl ((3,6-dichloropyridazin-4-yl)methyl)carbamate (20.0 g, 72.1 mmol) was added and the reaction mixture was stirred at 60°C for 2 hours. After completion, the reaction was cooled to room temperature, diluted with water (200 mL), and extracted with EtOAc (200 mL×3). The combined organic layers were washed with brine (200 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (PE / EtOAc) to give a mixture of the desired compounds (8.1 g, 36% yield) as a light brown solid, which was used as a mixture in the next step. LC-MS (ESI+): m / z rt=1.24 min, 310.19 [M+H] + and rt = 1.28 min, 310.15 [M+H] + .
[0196] Step 3: Synthesis of ethyl 5-(((tert-butoxycarbonyl)amino)methyl)-6-(1H-imidazol-1-yl)pyridazine-3-carboxylate and ethyl 4-(((tert-butoxycarbonyl)amino)methyl)-6-(1H-imidazol-1-yl)pyridazine-3-carboxylate: To a solution of a mixture of compounds tert-butyl ((6-chloro-3-(1H-imidazol-1-yl)pyridazin-4-yl)methyl)carbamate and tert-butyl ((3-chloro-6-(1H-imidazol-1-yl)pyridazin-4-yl)methyl)carbamate (6.5 g, 21.0 mmol) in EtOH (97.5 mL) was added sodium acetate (3.4 g, 41.9 mmol), and the resulting mixture was purged with argon for 10 minutes. Then, Pd(dppf)Cl2(0.77g, 1.0mmol) was added, and the reaction mixture was stirred at CO pressure (100psi) and 90°C for 24 hours. It was then cooled to room temperature and volatiles were evaporated under reduced pressure. NaHCO3(100mL) saturated aqueous solution was added and extracted with EtOAc(100mL×3). The combined organic layer was washed with brine (100mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (DCM / MeOH) to obtain a mixture of 5-(((tert-butoxycarbonyl)amino)methyl)-6-(1H-imidazole-1-yl)pyridazine-3-carboxylic acid ethyl ester and 4-(((tert-butoxycarbonyl)amino)methyl)-6-(1H-imidazole-1-yl)pyridazine-3-carboxylic acid ethyl ester (6.5g, 89% yield) as a brown solid. LC-MS: m / z rt = 1.36 min, 348.4 [M+H]+ and rt = 1.29 min, 348.3 [M+H]+.
[0197] Steps 4 and 5: Synthesis of methyl 2-(5-(((tert-butoxycarbonyl)amino)methyl)-6-(1H-imidazol-1-yl)pyridazine-3-carboxamido)-4,5-difluorobenzoate and methyl 2-(4-(((tert-butoxycarbonyl)amino)methyl)-6-(1H-imidazol-1-yl)pyridazine-3-carboxamido)-4,5-difluorobenzoate: Lithium hydroxide monohydrate (0.3 mL) in water (12.5 mL) was added to a 1% flask. To the solution of ethyl 5-(((tert-butoxycarbonyl)amino)methyl)-6-(1H-imidazole-1-yl)pyridazine-3-carboxylate and ethyl 4-(((tert-butoxycarbonyl)amino)methyl)-6-(1H-imidazole-1-yl)pyridazine-3-carboxylate (2.5 g, 7.2 mmol) in THF (25 mL), the resulting mixture was stirred at room temperature for 30 minutes. After the reaction was complete, THF was removed under reduced pressure, and the aqueous layer was acidified with 3N HCl (pH 4 to 5). Volatiles were removed by lyophilization to obtain a mixture of the corresponding carboxylic acids. The mixture was dissolved in DMF (41 mL), and methyl 4,5-difluoroanthranilate (3.2 g, 17.1 mmol) and DIPEA (7.38 mL, 42.40 mmol) were added. HATU (4.9 g, 12.8 mmol) was added to the reaction mixture and the reaction mixture was stirred at 80° C. for 7 hours. After completion, the reaction mixture was cooled to room temperature, diluted with a saturated aqueous solution of NaHCO (220 mL), and extracted with EtOAc (100 mL×3). The combined organic layers were washed with brine (200 mL), dried over anhydrous NaSO, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (DCM / MeOH) to give methyl 2-(5-(((tert-butoxycarbonyl)amino)methyl)-6-(1H-imidazol-1-yl)pyridazine-3-carboxamido)-4,5-difluorobenzoate (0.75 g, 21% yield) as a yellow solid and methyl 2-(4-(((tert-butoxycarbonyl)amino)methyl)-6-(1H-imidazol-1-yl)pyridazine-3-carboxamido)-4,5-difluorobenzoate (0.11 g, 3% yield) as a fluffy light brown solid. 5-Substituted Compounds:
[0198] 1 H NMR (400MHz, DMSO-d6); δ13.09 (s, 1H), 8.88-8.81 (m, 1H), 8.35 (s, 1H), 8.43 (s, 1H), 8.14-8.06 (m, 1H ), 7.89-7.84 (m, 2H), 7.26 (s, 1H), 4.37 (d, J=6.0Hz, 2H), 3.95 (s, 3H), 1.40 (s, 9H). LC-MS (ESI+): m / z 489.69[M+H]+ .
[0199] 4-Substituted compounds:
[0200] 1 H NMR (400MHz, DMSO-d6): δ12.99 (s, 1H), 8.84-8.77 (m, 2H), 8.15-8.07 (m, 3H), 7.36 (s , 1H), 7.29 (s, 1H), 4.79 (d, J=5.6Hz, 2H), 3.95 (s, 3H), 1.42 (s, 9H). LC-MS (ESI+): m / z 487.3[MH] - .
[0201] Step 6: Synthesis of methyl 2-(4-(aminomethyl)-6-(1H-imidazoles-1-yl)pyridazine-3-formamido)-4,5-difluorobenzoate 2: To a solution of 2-(4-(((tert-butoxycarbonyl)amino)methyl)-6-(1H-imidazoles-1-yl)pyridazine-3-formamido)-4,5-difluorobenzoate / ester (600 mg, 1.2 mmol) in DCM (0.5 mL) was added 4M HCl in dioxane (5 mL), and the reaction mixture was stirred at room temperature for 3 hours. After the reaction was complete, volatiles were removed under reduced pressure and ether (10 mL) was added to the residue. The solid obtained was filtered and dried to obtain compound 2 (HCl salt) (34 mg, 7% yield) as an off-white solid.
[0202] 1 H NMR (400MHz, DMSO-d6): δ13.10(s, 1H), 9.43(s, 1H), 8.91(s, 1H), 8.77-8.83(m, 4H), 8.44(s , 1H), 8.10-8.15 (m, 1H), 7.62 (s, 1H), 4.68 (t, J=5.2Hz, 2H), 3.96 (s, 3H). LC-MS (ESI+): m / z 389.2[M+H] + .
[0203] Compounds 7, 42, 43 and 74 were prepared by using a procedure similar to that used for the synthesis of compound 2.
[0204] Embodiment 3:
[0205] Scheme 5: Synthesis of compound 3:
[0206]
[0207] 7-ethynyl-6-fluoro-2-(6-(pyridin-4-yl)pyridazin-3-yl)-4H-benzo[d][1,3] Synthesis of oxazine-4-one (3): A suspension of compound 1 (36 mg, 0.1 mmol) in 0.5 mL of thionyl chloride was heated under reflux for 2 hours. Excess thionyl was then removed under vacuum. 2 mL of anhydrous acetonitrile was added to the solid, and a solution of DIPEA (35 μL, 0.2 mmol) in 2 mL of anhydrous acetonitrile was added at room temperature. After stirring for 30 minutes, the resulting precipitate was separated and washed with acetonitrile to obtain the product (28 mg, 80% yield).
[0208] 1 H NMR (400 MHz, DMSO) δ 8.91-8.82 (m, 2H), 8.63 (q, J = 9.0 Hz, 2H), 8.30-8.20 (m, 2H), 8.13 (d, J = 8.6 Hz, 1H), 8.08 (d, J = 6.2 Hz, 1H), 5.04 (s, 1H). MS-ESI: m / z 345.46 observed (M+H) +
[0209] Compounds 75, 80 and 93 were prepared by using a procedure similar to that used for the synthesis of compound 3.
[0210] Although the present disclosure has been described and illustrated in sufficient detail for those skilled in the art to make and use the disclosure, various alternatives, modifications and improvements will be apparent to those skilled in the art without departing from the spirit and scope of the claims.
[0211] All patents and publications mentioned herein are incorporated by reference to the same extent as if each individual publication was specifically and individually indicated to be incorporated by reference in its entirety.
Claims
1. A compound of formula (IA), or a pharmaceutically acceptable salt thereof in X is -N=C(R 1 )-, or-C(R 1 )=C(R 1 )-; R 1 Each is independently H, F, Cl, C1-C6-alkyl or halogenated C1-C6-alkyl; R 2 Selected from: -C(O)OR; R is selected from C1-C6-alkyl; Ring A is a 5- or 6-membered heteroaryl group comprising 2 or 3 N atoms, substituted by 1, 2 or 3 groups independently selected from: NH-benzyl, wherein the benzyl group is unsubstituted or substituted by C1-C6-alkoxy, The wavy lines indicate bonding locations.
2. The compound according to claim 1, wherein ring A is selected from any one of pyridazinyl, triazolyl, pyrimidinyl and pyridinyl, any one of which is substituted.
3. A compound selected from one of the following tables:
4. Use of a compound according to any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for stimulating the expression of an interferon gene in a human patient.
5. Use of a compound according to any one of claims 1 to 3 or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating tumors in a patient by stimulating the expression of interferon genes. The use according to claim 4 or 5, wherein the drug is administered orally or intratumorally.
7. The use according to claim 4 or 5, wherein the compound is formulated for administration to the patient as an antibody-drug conjugate or in a liposomal formulation.
8. The use according to claim 4 or 5, wherein the drug is used for combined administration with an effective dose of an immune checkpoint targeting drug.
9. The use according to claim 8, wherein the immune checkpoint targeted drug comprises an anti-PD-L1 antibody, an anti-PD-1 antibody, an anti-CTLA-4 antibody or an anti-4-1BB antibody.
10. The use according to claim 4 or 5, wherein the medicament is for administration in combination with ionizing radiation or an anticancer drug.
11. A pharmaceutical composition comprising the compound according to any one of claims 1 to 3 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
